CTOs on the Move


 
Entelo applies intelligence to big data to help modern recruiters identify, qualify and engage talent. Today, more than 700 customers of all sizes and industries trust Entelo to provide their talent acquisition teams with higher candidate engagement, actionable insights and increased productivity. The leader in recruiting automation, Entelo helps organizations like Capital One, Cisco, GE, Genentech, Netflix, Northrop Grumman and Target build their teams.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.entelo.com
  • 123 Mission Street 24th Floor
    San Francisco, CA USA 94105
  • Phone: 415.689.7774

Executives

Name Title Contact Details
Andrew Schafer
Chief Technology Officer Profile

Funding

Entelo raised $20M on 06/15/2017

Similar Companies

Celsius Therapeutics

Celsius Therapeutics is a community of scientists, technologists, clinicians and drug hunters leveraging single-cell RNA sequencing and genomic analysis to develop life-changing medicines. Our common goal is to markedly improve human health by integrating data, experience and insight. Located in Cambridge, Mass., our environment is rigorous, fast-paced and collaborative, bringing together passionate individuals who are making an impact. We inspire creativity and discovery by embracing an open culture that fosters innovation, teamwork and excellence. We are committed to attracting and retaining the best talent, and we believe that our growth and success will be driven by those who are inspired by our mission and share our values. If you`re curious, collaborative and relentless about making a difference in the lives of patients, join us!

MediQuest Therapeutics

MediQuest Therapeutics is a Maple Valley, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Donor Network of Arizona

Donor Network of Arizona is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Therics Inc

Therics Inc is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Plexium

Plexium is the premier, next-generation Targeted Protein Degradation (TPD) company seeking to discover a wide range of monovalent target protein degraders that address the limitations of heterobifunctional degraders and cereblon IMiDs. The company is powered by its proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. From molecular glues to monovalent degraders, Plexium is advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases. Due to its expertise in TPD, Plexium has entered into strategic collaborations with Amgen and AbbVie to discover and develop a wide range of new therapies from cancer to neurological diseases. Supported by high quality investors, Plexium is well positioned to transform medicine.